MarketPulse

regulatory scrutiny

16 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Regencell Bioscience Faces Class Action Over Alleged Market Manipulation Disclosures

Class action lawsuit filed against Regencell Bioscience for alleged false statements about market manipulation vulnerability and regulatory risks. Lead plaintiff deadline: June 23, 2026.
RGCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Regencell Bioscience Hit with Class Action Lawsuit Over Market Manipulation Claims

Class action lawsuit filed against Regencell Bioscience for alleged false statements regarding market manipulation vulnerability and regulatory exposure. Lead plaintiff deadline: June 23, 2026.
RGCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Atara Biotherapeutics Faces Class Action Over FDA Approval Claims

Class action lawsuit filed against Atara Biotherapeutics alleges false statements about FDA approval prospects. Investors must seek lead plaintiff status by May 22, 2026.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Securities Class Actions Target Regencell, Globant, Nektar Over Alleged Misstatements

Rosen Law Firm files class actions against $RGC, $GLOB, $NKTR alleging false statements. Investors have until June 23, 2026 to become lead plaintiffs.
RGCNKTRGLOBsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Filed Against Regencell Over Allegedly False Statements on Operations

Class action filed against Regencell Bioscience for allegedly false statements on operations and market manipulation vulnerabilities affecting investors during October 2024-October 2025 period.
RGCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Regencell Investors Sue Over Undisclosed DOJ Probe, Stock Plunges 18.56%

Class action lawsuit filed against Regencell Bioscience for alleged false statements and failure to disclose DOJ investigation into trading practices.
RGCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Regencell Faces Securities Class Action Over Alleged False Statements, Disclosure Failures

Rosen Law Firm filed class action lawsuit against Regencell Bioscience ($RGC) alleging false statements and regulatory risk non-disclosure. Lead plaintiff deadline: June 23, 2026.
RGCSESSES.WSGLOBsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Regencell Faces Class Action Lawsuit Over Market Manipulation Disclosures

Class action filed against $REGENCELL for alleged false statements regarding market manipulation vulnerability and regulatory exposure between October 2024-2025.
RGCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Gainey Mckenna & Egleston

Securities Suit Filed Against $RGC Over Alleged Market Manipulation Disclosure Gaps

Class action lawsuit filed against $RGC for failing to disclose market manipulation vulnerabilities. June 23, 2026 deadline for lead plaintiff claims.
RGCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Filed Against $RGC Over Alleged Market Manipulation Vulnerability

Law firm files class action against Regencell Bioscience ($RGC) alleging false statements about market manipulation risks. Investors urged to join case by June 23, 2026 deadline.
RGCsecurities fraudclass action lawsuit
The Motley FoolThe Motley Fool··Jack Delaney

Fintech Underdogs: Why $HOOD and $SOFI Could Reward Patient Long-Term Investors

Robinhood and SoFi emerge as long-term investment opportunities, expanding beyond core businesses into prediction markets and wealth management despite recent declines and significant volatility risks.
SOFIHOODfintechmarket volatility
BenzingaBenzinga··Eva Mathew

Ellison Pledges 30 Annual Films as Paramount-Skydance-WBD Deal Faces Scrutiny

Paramount Skydance CEO David Ellison defends $110B Warner Bros merger, commits to 30+ annual films with 45-day theatrical windows amid regulatory concerns.
WBDPSKYtheatrical releasesregulatory scrutiny
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Hit With Class Action Over Misleading FDA Study Claims

Class action lawsuit filed against $ATARAWITH alleging executives made false statements about manufacturing issues and ALLELE study deficiencies that could block FDA approval of tabelecleucel.
ATRAsecurities fraudclass action lawsuit
Investing.comInvesting.com··Jesse Cohen

Market Turmoil Opens Opportunity: Buy Ondas, Sell PDD This Week

Buy Ondas ahead of Q4 earnings with strong guidance revisions; sell PDD due to slowing growth, regulatory threats, and margin pressures.
PDDONDStechnical analysisstock market decline
BenzingaBenzinga··Kenneth Rapoza

UBS Stumbles Despite Strong Earnings as Legal Headwinds Overshadow Q4 Profit

UBS posts $1.2B Q4 profit but stock down 10% YTD amid mounting Credit Suisse legal liabilities and premium 17.75x P/E valuation relative to peers.
GSGSpAGSpCGSpDBAC+29banking sectorunderperformance
BenzingaBenzinga··Namrata Sen

Netflix Positioned as Frontrunner in Warner Bros. Assets Competition

Netflix leads bidding for Warner Bros. Discovery assets at $27.75 per share, combining HBO Max and studio operations. Deal awaits DOJ regulatory approval.
NFLXWBDPSKYbidding wartakeover bid